Patents by Inventor Marco Bezzi

Marco Bezzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Direct and Selective Inhibition of MDM4 for Treatment of Cancer
    Publication number: 20200392506
    Abstract: The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 17, 2020
    Inventors: Jean-Christophe Marine, Ernesto Guccione, Marco Bezzi
  • Direct and selective inhibition of MDM4 for treatment of cancer
    Patent number: 10767182
    Abstract: The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: September 8, 2020
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D, Agency for Science, Technology and Research
    Inventors: Jean-Christophe Marine, Ernesto Guccione, Marco Bezzi
  • DIRECT AND SELECTIVE INHIBITION OF MDM4 FOR TREATMENT OF CANCER
    Publication number: 20170314024
    Abstract: The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
    Type: Application
    Filed: November 16, 2015
    Publication date: November 2, 2017
    Inventors: Jean-Christophe Marine, Ernesto Guccione, Marco Bezzi